BBOT — BridgeBio Oncology Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1869105 ·
Last close
$7.75
Market Cap
$620.83M
52W High
$9.73
52W Low
$7.00
ADV30
342,200
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -46,179,000 | -42,106,000 | 417,646,000 | 52,658,000 | 45,366,000 |
| Dec 2025 | 0 | — | -43,408,000 | -38,797,000 | 448,381,000 | 373,687,000 | 37,285,000 |
| Sep 2025 | 0 | — | -49,181,000 | -44,757,000 | 484,793,000 | 408,741,000 | 38,093,000 |
| Jun 2025 | 0 | — | -30,093,000 | -28,435,000 | 151,253,000 | 31,518,000 | 378,986,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-130,212,000
Investing CF
$-227,447,000
Financing CF
$384,101,000
CapEx
$-468,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-527.99
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-398,673,000
Inventory
—
Receivables
$146,000
ST Investments
$199,617,000
EBIT TTM
$-168,861,000
Pretax Income TTM
$-154,095,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -145,819,000 | -134,044,000 | 448,381,000 | 37,285,000 | — | -113,894,000 |
| Dec 2024 | 0 | -80,863,000 | -74,275,000 | 164,301,000 | 342,938,000 | — | -55,027,000 |
| Dec 2023 | 0 | -64,771,000 | -64,699,000 | 5,942,000 | 121,583,000 | — | -52,079,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.14
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TRAX | First Tracks Biotherapeutics, Inc. | $615.50M | $17.64 | — |
| OMER | OMEROS CORP | $632.56M | $8.74 | — |
| RIGL | RIGEL PHARMACEUTICALS INC | $607.79M | $32.85 | — |
| ANL | Adlai Nortye Ltd. | $606.14M | $10.32 | — |
| ACRS | Aclaris Therapeutics, Inc. | $603.35M | $4.32 | — |
News headlines (Yahoo Finance, 1h cache)
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
2026-05-17 18:33 · Yahoo
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
2026-05-17 18:25 · Yahoo
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
2026-05-17 18:18 · Yahoo
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
2026-05-15 23:02 · Yahoo
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
2026-05-15 22:56 · Yahoo
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
2026-05-15 22:50 · Yahoo
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
2026-05-12 21:03 · Yahoo
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-05-12 20:05 · Yahoo
Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More
2026-05-11 11:58 · Yahoo
Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
2026-04-24 10:46 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.